Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer

Bradley A. Schiff, Andrea B. McMurphy, Samar A. Jasser, Maher N. Younes, Dao Doan, Orhan G. Yigitbasi, Seungwon Kim, Ge Zhou, Mahitosh Mandal, Benjamin N. Bekele, F. Christopher Holsinger, Steven I. Sherman, Sai Ching Yeung, Adel K. El-Naggar, Jeffrey N. Myers

Research output: Contribution to journalArticlepeer-review

135 Scopus citations

Fingerprint

Dive into the research topics of 'Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences